• Skip to main content
  • Skip to footer

Oklahoma Medical Research Foundation | OMRF

OMRF is an independent, nonprofit biomedical research institute dedicated to discoveries that make a difference.

  • About
    • General Information
    • Disease Research
    • Education & Outreach
    • Events
    • Jobs
    • Contact Us
  • Science
    • Scientist Directory
    • Research Programs
    • Research Centers
    • Core Facilities
    • Scientific Publications
    • Scientific Seminars
    • Technology Ventures
  • News
    • Media Resources
    • OMRF in the Media
    • OMRF News
    • OMRF Publications
    • OMRF Videos
  • Patients
    • Lupus (SLE)
    • MBTPS1 Related Disorders
    • Multiple Sclerosis
    • Rheumatoid Arthritis
    • Sarcoidosis
    • Sjögren’s Syndrome
    • Other Autoimmune Disorders
  • Donate
    • Donate Now
    • Tax Credit
    • Planned Giving
    • Vehicle Donations
    • Why We Give
    • Your Gift at Work
    • Donor Recognition
    • Contact

Primary Sidebar

  • About Us
  • Our Team
  • Clinical Trials
  • Contact Us
Home - Patient Studies - Rheumatoid Arthritis - Clinical Trials

Rheumatoid Arthritis

Clinical Trials

For more information on any of the studies listed below, call (405) 271-7805 or email clinic@omrf.org.

Anti-Inflammatory Effects of Honokiol on Activation of PBMC from Healthy Volunteers and RA Patients (ACTIVE)

ARA08: Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA) (ACTIVE – Open to Enrollment/Accrual)

Novel Mechanisms of IL-8 Regulation in Oklahoma Tribal Members Afflicted with Rheumatoid Arthritis (ACTIVE)

A 24-week, Phase 3, Multicentre, Randomised, Double blind, Efficacy and Safety Study Comparing GSK3196165 with Placebo and with Sarilumab, in Combination with Conventional Synthetic DMARDs in Participants with Moderately to Severely Active Rheumatoid Arthritis Who have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors, Protocol 202018 (ACTIVE – Open to Enrollment/Accrual)

A 52-week, Phase 3, Multicentre, Randomised, Double blind, Efficacy and Safety Study Comparing GSK3196165 with Placebo and with Tofacitinib, in Combination with Methotrexate in Participants with Moderately to Severely Active Rheumatoid Arthritis who have an Inadequate Response to Methotrexate, Protocol 201790 (ACTIVE – Open to Enrollment/Accrual)

Phase 3B/4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to a Tumor Necrosis Factor (TNF) Inhibitor in Subject with Rheumatoid Arthritis, Protocol A3921133 (ACTIVE – Closed to Enrollment/Accrual)

A Multi-Centre Long-Term Extension Study to Assess the Safety and Efficacy of GSK3196165 in the Treatment of Rheumatoid Arthritis Protocol 209564 (ACTIVE – Open to Enrollment/Accrual)

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis (RA-BRIDGE), Protocol I4V-MC-JAJA (ACTIVE – Closed to Enrollment/Accrual)

Before Footer

EEO/AA Employer/Vet/Disabled

Footer

  • Jobs
  • Directory
  • Donor Privacy Statement
  • Intranet
Charity navigator
United Way Give Smart OKC
Facebook Twitter YouTube Instagram Mail Linkedin
Administrator Log In